Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

20th November, 2026

Corporate Relationship Department
M/s. BSE Limited
Mumbai 400001

Scrip Code: 524816

The Manager - Listing
M/s. National Stock Exchange of India Ltd
Bandra (E), Mumbai 400051

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref:- Our earlier intimation dated 21st August, 2026

With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the receipt of Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage Formulations (FDF) Unit.

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

VENKAT RAMESH CHEKURI
Digitally signed by VENKAT RAMESH CHEKURI
Date: 2026.11.20 08:27:52 +05'30'

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

Encl: As above

Press Release

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

NATCO Pharma Limited, Finished Dosage Formulations (FDF) Receives Establishment Inspection Report (EIR) from U.S. FDA

Hyderabad, India, November 20th, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today receives Establishment Inspection Report (EIR) from US FDA Inspection at our Visakhapatnam, Andhra Pradesh, FDF Unit

Ref: Our letter dated August 21st 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, this is to inform you that:

The U.S. Food and Drug Administration (FDA) had conducted an inspection at the FDF manufacturing plant located in Parawada, Visakhapatnam, Andhra Pradesh, India, which was conducted from August 17th – August 21st, 2026. On conclusion of the inspection, the Company had received 4 (Four) observations in the Form-483. We hereby notify that the Company has received EIR from the U.S. FDA on the classification of the above referred inspection as Voluntary Action Indicated (VAI).

Please take the above information on record.

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets.

For further information please contact:

Rajeev Menon, Investor Relations

r.menon@natcopharma.co.in/investors@natcopharma.co.in